Nasrudin Hashi 1084248 Dr. Foard November 18, 2019 Hello, my name is Nasrudin Hashi I’m a representative for Acasti Pharma. Have you ever pondered how many people yearly suffer from cardiometabolic disorders? 25% of the world’s adults suffer from this disorder and it is only going up, it is raising red flags across the globe. Cardiometabolic disorders also known as cardiometabolic syndrome (CMS) is a blend of metabolic dysfunctions mainly insulin resistance, impaired glucose tolerance, dyslipidemia, and etc. “Cardiometabolic disorder is now recognized as a disease entity by the World Health Organization and the American Society of Endocrinology” (Ferdinand, K. C. 2018, August). People with cardiometabolic disorder are more likely to die from coronary heart disease. This event is a reoccurring problem, if not treated properly cardiometabolic disorder has proven to be fatal. The horrific part is that it’s hard to know you have cardiometabolic disorder but on the bright side there are a few signs such as increased blood pressure, high blood sugar levels, unneeded fat around the waist, and low levels of good cholesterol. Cardiometabolic disorder may result in the hardening of arteries, diabetes, heart attack, stroke, and many more. There are a few medical ways to help stop or prevent it then that’s when Acasti’s steps in. Acastis mission is to innovate the products of pharmaceutical studies we designed to help better the lives of cardiometabolic disorders penitents. We are a sturdy company working for the betterment of the community as a whole. Acasti Pharma is in the works of a first-class omega-3 therapeutic treatment for all our patients. Our main source is from Krill it is designated too bring a hattrick of cardiometabolic health benefits to patients. The treatment has omeaga-3s deprived from fish oils and 60% of omega-3s are naturally bound to phospholipids and the rest are fatty acids. CaPre, Acasti’s prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil. Acasti’s growing global patent portfolio encompasses CaPre and its composition until the last of its patents expire in 2031. Acasti currently holds numerous compositions of matter and method of use patents in various jurisdictions around the world including in the U.S., China, Japan, Taiwan and Australia, and we have numerous additional patents pending. (Acasit Pharma). All clinical production lots of CaPre for the trilogy Phase 3 program have been completed. Acasti and our contract manufacturing partners have made a unique and innovative continuous manufacturing process for CaPre that will allow the company to efficiently scale-up the volume of CaPre as needed for commercial launch to get the medicine too everyone that needs it. We even teamed up with Aker BioMarine to supply us with Krill Oil for CaPre. Raw Krill Oil (RKO) is the starting material used by Acasti to make CaPre, which is then further processed via a series of complex and proprietary extraction and purification manufacturing steps to produce the drug substance for CaPre. This agreement is intended to ensure an adequate krill oil supply to meet Acasti’s anticipated raw material needs through at least mid-2021, including scale-up of production to build future inventory for commercial launch. Furthermore, the parties have agreed to contemplate future commercial collaborations. Aker Bio marine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. The company develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and all the way to customers around the world (Our Science. n.d.). Acasti pharma is for the people and will always be if you have a loved one that is suffering from cardiometabolic disorder don’t be afraid to ask your doctor about CaPre by Acasti Pharma. It could help save their life at the end of the day we are not all immune to sickness what with Acasti Pharma We can help eliminate the threat of cardiometabolic disorder and live long lives knowing that Acasti Pharma is working day in and day out too protect all of us from this terrifying and annoying disorder. That ruined so many happy live and that brought so many people’s lives to an early end. Work Cited AHA 2019 Heart Disease and Stroke Statistics. (n.d.). Retrieved from https://www.acc.org/latest-incardiology/ten-points-to-remember/2019/02/15/14/39/aha-2019-heart-disease-and-strokestatistics. Ferdinand, K. C. (2018, August). Global perspectives on cardiometabolic risk and cardiovascular disease: from basic science to bedside. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123208/. Our Science. (n.d.). Retrieved from https://www.acastipharma.com/en/our-science. Saklayen, M. G. (2018, February 26). The Global Epidemic of the Metabolic Syndrome. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866840/. Saljoughian, M. (2017, February 16). Cardiometabolic Syndrome: A Global Health Issue. Retrieved from https://www.uspharmacist.com/article/cardiometabolic-syndrome-a-global-health-issue.
